Myeloperoxidase Demand increases worldwide for Lee Biosolutions, Inc

Nov. 14, 2007 - PRLog -- St. Louis, MO.  Lee Biosolutions  ( http://www.leebio.com/ ) has increased its capacity for the higher than expected demand for high quality human Myeloperoxidase products that have been qualified by major clinical diagnsotic companies worldwide. Myeloperoxidase antigen  (http://www.leebio.com/products/details.html?uid=166 ) and Myeloperoxidase antibodies demand is expected to increase in double digits every year for the next 5 years.

As a leading raw materials manufacturers, specializing in human cardiac markers
( http://www.leebio.com/products/index.html?search=cardiac%20markers&submit=Search ) , Lee Biosolution has been a prefered supplier for Myeloperoxidase, troponin, myoglobin, Lactate dehydrogenase isoenzymes and creatine kinase isoenzymes to the diagnostic market for decades. Lee Bio's products is used in calibrators and controls on mass assay platforms from major diagnostic companies worldwide.

The New England Journal of Medicine published an article on October 23, 2003  that explains how a single initial measurement of plasma myeloperoxidase (mpo), which is found in white blood cells, independently predicts the early risk of cardiovascular disease. In addition, myeloperoxidase levels can predict the risk of major adverse cardiac events such as ischemia, myocardial infarction, and congestive heart failure, as well as heart cancer, Multiple Sclerosis, and other ailments.

This information was made possible by a study completed by the Cleveland Clinic Foundation. Their study consisted of 604 sequential emergency room patients that were experiencing chest pain. The results of the study show that the patients with the highest levels of myeloperoxidase face a significantly higher risk of a cardiac crisis within two months.

Lee Biosolutions provides proteins, enzymes and other materials to research facilities around the country that develop tests in order to advance the healthcare industry. By providing solutions on demand, Lee Biosolutions has become the preferred source for myeloperoxidase.

Lee Bio has been producing myeloperoxidase for many years, and holds the best knowledge, capabilities and capacity for customization to provide myeloperoxidase to meet any application.

Experts are eager to pursue the vast array of possibilities for myeloperoxidase as outlined in the Cleveland Clinic study, calling the study a major breakthrough that could revolutionize testing for and prevention of many ailments, including cardiovascular disease.

Doctors believe that myeloperoxidase blood tests would first be used in emergency rooms to distinguish patients who are genuinely at risk of a cardiac emergency from the millions who have chest pain from other causes. Eventually, the MPO test may be offered in doctors' offices as part of a battery of blood tests capable of identifying those who have heart disease but aren't aware. Doctors will be able to diagnose an imminent heart attack sooner and act quickly to prevent it.

For more information about myeloperoxidase and other cardiac markers please contact:

Lee Biosolutions, Inc
2924 Mary Ave
St. Louis, MO 63144
Tel: 314-968-1091
www.leebio. . LeeBio.com.

# # #

Lee Biosolutions, Inc specializes in the development and purification of high quality BioMarkers for the Immunodiagnostic, clinical diagnostic and pharmaceutical industry worldwide. We supply reliable high quality human and animal enzymes and proteins, cardiac markers, tumor markers, acute phase proteins, coagulation proteins and immunoassay biomarkers.

Website: www.leebio.com